Rejuvenating Immunity Through T Cell Regeneration

ProTgen is pioneering a new class of regenerative cell therapies that restore thymic function and replenish the T cell repertoire—unlocking new potential in cancer, autoimmune disease, and aging.

The Problem

Cancer treatments (chemo, radiation, HSCT transplant) impair immune recovery

Incomplete immune recovery weakens therapy efficacy and leaves patients vulnerable to relapse, infections

Our Science

Rebuilding the Immune System’s Master Organ

The thymus is essential for generating diverse, functional T cells—but it involutes with age and treatment, weakening immune defense. ProTgen’s proprietary soluble Notch ligands enable scalable production of proT cells, which home to and regenerate the thymus, restoring immune competence.

The Solution

Novel platform generates progenitor T (ProT) cells to restore immune function to treat cancer and beyond.

  • Off-the-shelf scalability

  • Cost efficiency vs. CAR-T

  • Potential for broad use

Clinical Strategy

Allo HSCT → solid tumors → universal iPSC

Near-term milestones derisk the platform

FIH trials expected in 2027

NEXT GENERATION CELL THERAPY

Rejuvenating the immune system’s master organ by delivering ProT cells to treat cancer, autoimmune diseases, and beyond

Oncology

Enhancing checkpoint inhibitors, bispecifics, and vaccines

Autoimmune & Inflammatory Diseases

Rebalancing immune tolerance

Aging & Immunosenescence

Rejuvenating immune function in older adults

Our staged development strategy includes:

1st Gen:

Allogeneic proT cells for HSCT

2nd Gen:

Autologous proT cells for solid tumors

3rd Gen:

iPSC-derived universal proT cells - editable, scalable, off-the-shelf

Our Medicines

ProT Cells: A New Frontier in Regenerative Immunotherapy

ProTgen’s platform produces proT cells capable of thymic repair and T cell regeneration. These cells restore immune diversity, improving outcomes across:

Our Team

Built by Leaders in T Cell Biology and Cell Therapy

Carter Cliff, CEO

Mahmood Mohtashami, Director of Research

Juan Carlos Zuñiga-Pflücker

Founded by world-renowed experts in Notch signaling and T cell development, ProTgen combines deep scientific insight with proven biotech leadership.

Board of Directors

Monet Goode

Eleanor Parks

Emmet Marsh

Our Investors

Backed by Visionary Partners